95 related articles for article (PubMed ID: 7999792)
1. Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells.
Staron K; Kowalska-Loth B; Zabek J; Czerwinski RM; Nieznanski K; Szumiel I
Biochim Biophys Acta; 1995 Jan; 1260(1):35-42. PubMed ID: 7999792
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism.
Staron K; Kowalska-Loth B; Nieznanski K; Szumiel I
Carcinogenesis; 1996 Mar; 17(3):383-7. PubMed ID: 8631120
[TBL] [Abstract][Full Text] [Related]
3. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Szumiel I
Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
5. Reduced sensitivity to camptothecin of topoisomerase I from a L5178Y mouse lymphoma subline sensitive to X-radiation.
Kowalska-Loth B; Staron K; Buraczewska I; Szumiel I; Kapiszewska M; Lange CS
Biochim Biophys Acta; 1993 Feb; 1172(1-2):117-23. PubMed ID: 8382526
[TBL] [Abstract][Full Text] [Related]
6. PKA controls a level of topoisomerase I mRNA in mouse L5178Y lymphoma cells treated with db-cAMP.
Czerwinski RM; Nieznanski K; Sochanowicz B; Staron K
Mol Biol Rep; 1994 Mar; 19(2):93-7. PubMed ID: 8072495
[TBL] [Abstract][Full Text] [Related]
7. The sensitivity to camptothecin of DNA topoisomerase I in L5178Y-S lymphoma cells.
Staron K; Kowalska-Loth B; Szumiel I
Carcinogenesis; 1994 Dec; 15(12):2953-5. PubMed ID: 8001262
[TBL] [Abstract][Full Text] [Related]
8. Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive.
Szumiel I; Buraczewska I; Gradzka I; Gasinska A
Int J Radiat Biol; 1995 Apr; 67(4):441-8. PubMed ID: 7738407
[TBL] [Abstract][Full Text] [Related]
9. DNA repair, cell cycle progression and cell death following camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Skierski J; Szumiel I
Cell Biochem Funct; 1998 Dec; 16(4):239-52. PubMed ID: 9857486
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the effect of camptothecin in x-irradiated L5178Y-R and L5178Y-S cells by benzamide.
Gradzka I; Iwaneńko T; Kruszewski M; Szumiel I; Kapiszewska M; Lange CS; Afanasjev G
Radiat Environ Biophys; 1996 Aug; 35(3):185-91. PubMed ID: 8880961
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to inhibitors of type II topoisomerases from mouse L5178Y lymphoma strains that are resistant or sensitive to X-radiation.
Staron K; Kowalska-Loth B; Szumiel I; Buraczewska I
Mutat Res; 1993 Feb; 285(2):175-9. PubMed ID: 7678889
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
14. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
15. Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line.
St-Amant C; Lussier S; Lehoux J; Laberge RM; Boissonneault G
Biochem Cell Biol; 2006 Feb; 84(1):55-66. PubMed ID: 16462890
[TBL] [Abstract][Full Text] [Related]
16. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Xenopus laevis DNA topoisomerase I activity by phosphorylation in vitro.
Kaiserman HB; Ingebritsen TS; Benbow RM
Biochemistry; 1988 May; 27(9):3216-22. PubMed ID: 2839226
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
[TBL] [Abstract][Full Text] [Related]
19. The response of L5178Y lymphoma sublines to oxidative stress: antioxidant defence, iron content and nuclear translocation of the p65 subunit of NF-kappaB.
Bouzyk E; Gradzka I; Iwaneńko T; Kruszewski M; Sochanowicz B; Szumiel I
Acta Biochim Pol; 2000; 47(4):881-8. PubMed ID: 11996111
[TBL] [Abstract][Full Text] [Related]
20. Poly ADP-ribosylation in two L5178Y murine lymphoma sublines differentially sensitive to DNA-damaging agents.
Kleczkowska HE; Malanga M; Szumiel I; Althaus FR
Int J Radiat Biol; 2002 Jun; 78(6):527-34. PubMed ID: 12065056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
